AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3027604 — intervention group
Group type: COMPARATOR
Intervention: Prenalterol (2 mg)
Number of subjects: 0
Study 3027604 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (250 micrograms)
Number of subjects: 0
Study 3027604 — intervention group
Group type: COMPARATOR
Intervention: Yohimbine (effective dose)
Number of subjects: 0
Study 3027604 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine at high infusion rates
Number of subjects: 0
Study 31300288 — intervention group
Group type: EXPERIMENTAL
Intervention: 23vPPV
Number of subjects: 215
Study 31300288 — intervention group
Group type: COMPARATOR
Intervention: PCV7 + 23vPPV
Number of subjects: 215
Study 28028194 — intervention group
Group type: EXPERIMENTAL
Intervention: Probenecid (500-1000 mg/d)
Number of subjects: 149
Study 28028194 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300-600 mg/d)
Number of subjects: 149
Study 28028194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study 27909139 — intervention group
Group type: EXPERIMENTAL
Intervention: SBI-087 (200 mg)
Number of subjects: 210
Study 27909139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 24828019 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate-5: 5 mg/day folate supplements
Number of subjects: 81
Study 24828019 — intervention group
Group type: COMPARATOR
Intervention: Folate-1: 1 mg/day folate supplements
Number of subjects: 81
Study 24828019 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 21751197 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/m² clofarabine daily × 5 days
Number of subjects: 58
Study 21751197 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m² clofarabine daily × 5 days
Number of subjects: 58
Study 21751197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses of clofarabine
Number of subjects: 58
Study 21751197 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/m² clofarabine
Number of subjects: 58
Study 21751197 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/m² clofarabine
Number of subjects: 58
Study 19464029 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy (surgery group; n = 19)
Number of subjects: 39
Study 19464029 — intervention group
Group type: COMPARATOR
Intervention: Expectant management (control group; n = 20)
Number of subjects: 39
Study 17764554 — intervention group
Group type: EXPERIMENTAL
Intervention: LCS AP glide prosthesis
Number of subjects: 0
Study 17764554 — intervention group
Group type: COMPARATOR
Intervention: Rotating platform prosthesis
Number of subjects: 0
Study 15333398 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-related symptom distress scale (SDS) questionnaire
Number of subjects: 193
Study 11070749 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Propofol
Number of subjects: 45
Study 11070749 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 45
Study 11070749 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 45
Study 8881132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose of nadroparin calcium (7500 anti-Xa IC units)
Number of subjects: 283
Study 8881132 — intervention group
Group type: COMPARATOR
Intervention: Variable dose of nadroparin calcium (100 to 150 anti-Xa IC units/kg)
Number of subjects: 283
Study 1576050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (300 mg)
Number of subjects: 24
Study 1576050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (600 mg)
Number of subjects: 24
Study 1576050 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral micronized progesterone (1200 mg)
Number of subjects: 24
Study 1576050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3831331 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative learning situation
Number of subjects: 48
Study 3831331 — intervention group
Group type: COMPARATOR
Intervention: Individualistic learning situation
Number of subjects: 48
Study 3534632 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐alpha‐TPG-fenoterol
Number of subjects: 26
Study 3534632 — intervention group
Group type: COMPARATOR
Intervention: Placebo-fenoterol
Number of subjects: 26
Study 29221945 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 260
Study 29221945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroids
Number of subjects: 0
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional corticosteroids
Number of subjects: 0
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids
Number of subjects: 0
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional immunosuppressants
Number of subjects: 0
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study 28127561 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0
Study 26193492 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided interlimb force coupling training
Number of subjects: 33
Study 26193492 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 23023231 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose plain radiography
Number of subjects: 323
Study 23023231 — intervention group
Group type: COMPARATOR
Intervention: 50% reduced dose plain radiography
Number of subjects: 323
Study 20199208 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa and complementary scalp electro-acupuncture
Number of subjects: 10
Study 20199208 — intervention group
Group type: COMPARATOR
Intervention: Levodopa alone (control)
Number of subjects: 10
Study 18312042 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate (18 mg to 54 mg)
Number of subjects: 145
Study 18312042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 18312042 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS methylphenidate
Number of subjects: 145
Study 17134517 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) program, three times per week for 10 weeks
Number of subjects: 32
Study 17134517 — intervention group
Group type: COMPARATOR
Intervention: Brief advice control group
Number of subjects: 32
Study 17134517 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Resistance Training (PRT) program
Number of subjects: 32
Study 12940195 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide 150 mg/day
Number of subjects: 8113
Study 12940195 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8113
Study 10863677 — intervention group
Group type: EXPERIMENTAL
Intervention: Short bouts of walking (10-15 minutes)
Number of subjects: 0
Study 10863677 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery from walking (10-15 minutes)
Number of subjects: 0
Study 9333057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin 500 mg
Number of subjects: 40
Study 9333057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin 500 mg
Number of subjects: 40
Study 9333057 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral levofloxacin formulations
Number of subjects: 40
Study 9333057 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous levofloxacin infusion
Number of subjects: 40
Study 8471403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fengabine 200 mg
Number of subjects: 0
Study 8471403 — intervention group
Group type: EXPERIMENTAL
Intervention: Fengabine 400 mg
Number of subjects: 0
Study 8471403 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study 3836854 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 749 RP (2 mg/kg)
Number of subjects: 6
Study 3836854 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29220295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2 given once a week
Number of subjects: 300
Study 29220295 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 given once every 3 weeks
Number of subjects: 300
Study 27576882 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic single-site surgery (LESS)
Number of subjects: 20
Study 27576882 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic (CL) surgery
Number of subjects: 20
Study 25034805 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaded white tea
Number of subjects: 18
Study 25034805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary green tea (Sagara)
Number of subjects: 18
Study 25034805 — intervention group
Group type: COMPARATOR
Intervention: Warm water
Number of subjects: 18
Study 22695039 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus salivarius Ls‐33 (10 CFU)
Number of subjects: 50
Study 22695039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 19477881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette 2 mg)
Number of subjects: 9
Study 18705297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 800mg/daily (group M1)
Number of subjects: 75
Study 18705297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6gr 10 days/month (group M2)
Number of subjects: 75
Study 18705297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 800mg/daily + Lactobacillus casei DG 16 billion/day for 10 days/month (group LM1)
Number of subjects: 75
Study 18705297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine 1.6gr + Lactobacillus casei DG 16 billion/day for 10 days/month (group LM2)
Number of subjects: 75
Study 18705297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei DG 16 billion/day for 10 days/month (group L)
Number of subjects: 75
Study 16170253 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride (AMH)
Number of subjects: 27
Study 16170253 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 27
Study 12538221 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch in saline (HS‐NS)
Number of subjects: 90
Study 12538221 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hetastarch in balanced salt (HS‐BS)
Number of subjects: 90
Study 12538221 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 90
Study 11151579 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐stage endosseous root‐form implants (3 different implant systems)
Number of subjects: 89
Study 11151579 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose (FPG) and glycosylated hemoglobin (HbA1c) values
Number of subjects: 89
Study 9019576 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial and paraaxial fluorophotometry during acute phase of optic neuropathies
Number of subjects: 21
Study 9019576 — intervention group
Group type: EXPERIMENTAL
Intervention: Axial and paraaxial fluorophotometry during late phase of optic neuropathies
Number of subjects: 21
Study 9019576 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy eyes)
Number of subjects: 21
Study 1290315 — intervention group
Group type: EXPERIMENTAL
Intervention: Prudent diet plus at least 400 g/day of fruits and vegetables rich in dietary fibre and antioxidants, followed by moderate exercise (brisk walking and spot running) for 20 weeks after an initial 4-week diet period.
Number of subjects: 463
Study 1290315 — intervention group
Group type: COMPARATOR
Intervention: Prudent diet only for 4 weeks, followed by no exercise for 20 weeks.
Number of subjects: 463
Study 6363395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intramuscular neuroleptization at 10 mg per dose
Number of subjects: 20
Study 6363395 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid intramuscular neuroleptization at 2 mg per dose
Number of subjects: 20
Study 29898587 — intervention group
Group type: COMPARATOR
Intervention: BoNT‐A monotherapy (N=18)
Number of subjects: 35
Study 29898587 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT‐A plus physical therapy (PT) (N=17)
Number of subjects: 35
Study 28851729 — intervention group
Group type: EXPERIMENTAL
Intervention: iECG (AliveCor Kardia monitor)
Number of subjects: 1001
Study 28851729 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 1001
Study 28851729 — intervention group
Group type: EXPERIMENTAL
Intervention: iECG
Number of subjects: 1001
Study 26873817 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (greater patient involvement and information on individual fracture risk)
Number of subjects: 816
Study 26873817 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (standard clinical practice)
Number of subjects: 816
Study 25079942 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supervision (quarterly skills-based supervision by a district eye coordinator)
Number of subjects: 343
Study 25079942 — intervention group
Group type: COMPARATOR
Intervention: Routine supervision (existing supervision practices)
Number of subjects: 343
Study 25079942 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced supervision
Number of subjects: 343
Study 25079942 — intervention group
Group type: COMPARATOR
Intervention: Routine supervision
Number of subjects: 343
Study 22476378 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exercise training during pregnancy
Number of subjects: 118
Study 22476378 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising low-risk women
Number of subjects: 118
Study 19576299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) delivered via video teleconferencing (VTC)
Number of subjects: 126
Study 19576299 — intervention group
Group type: COMPARATOR
Intervention: In-person control condition
Number of subjects: 126
Study 19576299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost analysis of VTC and in-person modalities
Number of subjects: 126
Study 17496732 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromium picolinate and biotin (CPB)
Number of subjects: 36
Study 17496732 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 15246905 — intervention group
Group type: EXPERIMENTAL
Intervention: Once daily oral nitrates
Number of subjects: 0
Study 15246905 — intervention group
Group type: COMPARATOR
Intervention: Twice daily oral nitrates
Number of subjects: 0
Study 11412645 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP-TAZ)
Number of subjects: 137
Study 11412645 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin (IMI)
Number of subjects: 137
Study 11412645 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (PIP-TAZ and IMI)
Number of subjects: 137
Study 9756226 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific information pamphlet and a general preoperative counselling video
Number of subjects: 30
Study 9756226 — intervention group
Group type: COMPARATOR
Intervention: Video alone
Number of subjects: 30
Study 9756226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 7882263 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative discharge planning (CNS and social worker)
Number of subjects: 64
Study 7882263 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge planning (Control group not explicitly mentioned)
Number of subjects: 64
Study 3204250 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (theophylline) administered via constant intravenous infusion at mean levels of 15 +/- 2 mg/L SD
Number of subjects: 7
Study 3204250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 29429134 — intervention group
Group type: EXPERIMENTAL
Intervention: Building on Family Strengths Program
Number of subjects: 110
Study 28118695 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 57
Study 28118695 — intervention group
Group type: COMPARATOR
Intervention: No arm sling
Number of subjects: 57
Study 24633212 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 60
Study 24633212 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 24633212 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 24602137 — intervention group
Group type: EXPERIMENTAL
Intervention: HM30181 (15, 60, or 180 mg)
Number of subjects: 18
Study 24602137 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 18
Study 24602137 — intervention group
Group type: COMPARATOR
Intervention: Loperamide alone
Number of subjects: 18
Study 22956397 — intervention group
Group type: EXPERIMENTAL
Intervention: One-session motivational interviewing (MI)
Number of subjects: 100
Study 22956397 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session motivational interviewing (MI)
Number of subjects: 100
Study 22956397 — intervention group
Group type: COMPARATOR
Intervention: Standard of care control
Number of subjects: 100
Study 19954057 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable plaque group
Number of subjects: 0
Study 19954057 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerable plaque group
Number of subjects: 0
Study 19954057 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 17889463 — intervention group
Group type: EXPERIMENTAL
Intervention: 1mg estradiol valerate/2mg dienogest (1EV/2DNG)
Number of subjects: 324
Study 17889463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 15351191 — intervention group
Group type: EXPERIMENTAL
Intervention: EVAR
Number of subjects: 1082
Study 15351191 — intervention group
Group type: COMPARATOR
Intervention: Open AAA repair
Number of subjects: 1082
Study 11316916 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 0
Study 11316916 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg/day
Number of subjects: 0
Study 11316916 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 0
Study 9875727 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal lesions of the lateral cerebellar cortex and nuclei
Number of subjects: 0
Study 9875727 — intervention group
Group type: COMPARATOR
Intervention: Lesions of the mesial cerebellum and vermis
Number of subjects: 0
Study 9197805 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom motivation education class
Number of subjects: 205
Study 9197805 — intervention group
Group type: COMPARATOR
Intervention: Treatment for STD (Comparison Group)
Number of subjects: 205
Study 2293320 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine
Number of subjects: 29
Study 2293320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine
Number of subjects: 29
Study 2293320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 2293320 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 29
Study 6118215 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (200 to 600 mg twice daily)
Number of subjects: 15
Study 6118215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6118215 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 15
Study 31686094 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (LipiDiDiet product)
Number of subjects: 278
Study 31686094 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 278
Study 26732026 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group consuming fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp lactis BB-12 (109 colony-forming units/d each) for 6 weeks
Number of subjects: 50
Study 26732026 — intervention group
Group type: COMPARATOR
Intervention: Control group consuming conventional fermented milk for 6 weeks
Number of subjects: 50
Study 26732026 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 50
Study 25980900 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 1663
Study 25980900 — intervention group
Group type: COMPARATOR
Intervention: Insulin degludec
Number of subjects: 1663
Study 25980900 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 1663
Study 25951165 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g in 1000 mL of 0.9% saline solution infused over 24 hours for each of the 3 preoperative days)
Number of subjects: 60
Study 25951165 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1000 mL of 0.9% saline solution for the same time period)
Number of subjects: 60
Study 22770431 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bleaching technique with 38% hydrogen peroxide gel for one hour
Number of subjects: 80
Study 22770431 — intervention group
Group type: COMPARATOR
Intervention: Sealed bleaching technique with 38% hydrogen peroxide gel for one hour
Number of subjects: 80
Study 21807566 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 20
Number of subjects: 660
Study 21807566 — intervention group
Group type: COMPARATOR
Intervention: BTDS 5
Number of subjects: 660
Study 21807566 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone 40 mg/day
Number of subjects: 660
Study 18586992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive somatotherapy regimens
Number of subjects: 306
Study 18586992 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to care (lack of telephone access)
Number of subjects: 306
Study 18586992 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to care (life obligations and commitments)
Number of subjects: 306
Study 18586992 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior suicide attempts
Number of subjects: 306
Study 16820257 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg/day bid + Sertraline 50 mg/day od
Number of subjects: 40
Study 16820257 — intervention group
Group type: COMPARATOR
Intervention: Venlafaxine XR 75 mg/day od (increased to 150 mg/day od in week 2)
Number of subjects: 40
Study 12611754 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.10 mg/day of transdermal 17beta-estradiol
Number of subjects: 20
Study 12611754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20